Mainz Biomed NV (NASDAQ:QUCY) Short Interest Up 996.3% in May

Mainz Biomed NV (NASDAQ:QUCY) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 10,530,990 shares, a growth of 996.3% from the April 30th total of 960,587 shares. Based on an average daily volume of 79,673,861 shares, the days-to-cover ratio is currently 0.1 days. Approximately 79.6% of the company’s shares are short sold.

Mainz Biomed Price Performance

Shares of QUCY stock traded down $0.54 on Wednesday, hitting $2.93. The stock had a trading volume of 6,415,368 shares, compared to its average volume of 50,886,420. The firm has a market capitalization of $42.95 million, a price-to-earnings ratio of -0.04 and a beta of 0.42. Mainz Biomed has a 1 year low of $0.30 and a 1 year high of $4.93. The firm has a 50 day moving average of $1.04.

Mainz Biomed (NASDAQ:QUCY) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $0.13 million during the quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on QUCY shares. Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Maxim Group downgraded Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Mainz Biomed has an average rating of “Reduce”.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.